Health Reference Series: Drug Abuse Sourcebook

Editor: Shannon, Joyce Brennfleck
Publication Year: 2016
Publisher: Omnigraphics, Inc.

Single-User Purchase Price: $85.00
Unlimited-User Purchase Price: $127.50
ISBN: 978-0-7808-1516-2
Category: Health & Medicine - Pharmaceutical Science
Image Count: 21
Book Status: Available
Table of Contents

Provides basic consumer health information about the abuse of illegal drugs and misuse of prescription and over-the-counter medications, along with facts about prevention, treatment, and recovery.

Share this

This book is found in the following Credo Collections:

Table of Contents

  • Preface
  • Part I: Facts and Statistics about Drug Abuse in the United States
  • Chapter 1—Prevalence of Illicit Drug Use and Substance Abuse
  • Chapter 2—Injection Drug Use and Related Risk Behaviors
  • Chapter 3—Drug Abuse and Related Hospitalization Costs
  • Section 3.1—Substance Abuse Cost to Society
  • Section 3.2—Drug-Related Hospital Emergency Room Visits
  • Section 3.3—Deaths from Drug Overdoses
  • Chapter 4—Understanding the Legal Use of Controlled Substances
  • Section 4.1—Schedule Classifications for Controlled Substances
  • Section 4.2—Prescriptions for Controlled Substances
  • Section 4.3—Purchasing Prescribed Controlled Substances over the Internet
  • Section 4.4—Is Marijuana Medicine?
  • Section 4.5—Overview of the Medical Marijuana Debate
  • Chapter 5—Regulations Regarding Controlled Substances
  • Section 5.1—The Controlled Substances Act
  • Section 5.2—Combat Methamphetamine Epidemic Act
  • Chapter 6—Substance Abuse Treatment Statistics
  • Section 6.1—Treatment Received for Substance Abuse
  • Section 6.2—Increase in Treatment Admissions for Prescription Pain Medicine Abuse
  • Section 6.3—Predictors of Substance Abuse Treatment Completion
  • Part II: Drug Abuse and Specific Populations
  • Chapter 7—Initiation of Drug Abuse
  • Section 7.1—Estimates of Drug Use Initiation
  • Section 7.2—Dependence Following Drug Use Initiation
  • Chapter 8—The Effect of Adult Substance Abuse on Children
  • Section 8.1—Concerns about Drug Abuse during Pregnancy
  • Section 8.2—Negative Consequences of Prenatal Exposure to Drugs
  • Section 8.3—Drug Endangered Children
  • Chapter 9—Adolescent Drug Abuse
  • Section 9.1—Trends in Adolescent Drug Abuse
  • Section 9.2—Understanding the Risk Factors and Reasons Why Adolescents Try Drugs and Alcohol
  • Section 9.3—Adolescent Marijuana Use Increases over Alcohol and Tobacco
  • Section 9.4—Bullying and Youth Substance Use
  • Chapter 10—Drug Use among College Students
  • Chapter 11—Substance Abuse Issues of Concern to Women
  • Section 11.1—Substance Use in Women
  • Section 11.2—Patterns and Prevalence of Substance Use Among Women
  • Section 11.3—What Women Need to Know about Date Rape Drugs
  • Section 11.4—Prescription Painkiller Overdoses among Women
  • Chapter 12—Substance Abuse in the Workplace
  • Chapter 13—Veterans and Drug Abuse
  • Chapter 14—Drug Abuse in Other Populations
  • Section 14.1—Inmate Populations and Substance Abuse
  • Section 14.2—Substance Use Disorders in People with Disabilities
  • Section 14.3—Seniors and Drug Abuse
  • Part III: Drugs of Abuse
  • Chapter 15—Drugs Used as Performance Enhancers
  • Section 15.1—Anabolic Steroids
  • Section 15.2-Clenbuterol
  • Section 15.3—Human Growth Hormone (hGH)
  • Chapter 16—Cannabinoids
  • Chapter 17—Date Rape Drugs / Club Drugs
  • Section 17.1—Introduction to Club Drugs
  • Section 17.2—Gamma Hydroxybutyrate (GHB)
  • Section 17.3-Ketamine
  • Section 17.4-Rohypnol
  • Chapter 18—Hallucinogenic Drugs
  • Section 18.1—Introduction to Hallucinogens
  • Section 18.2-Synthetic Drugs: 2C-I and 2C-T-7 (Blue Mystic)
  • Section 18.3 — Alpha-Methyltryptamine (Spirals)
  • Section 18.4—N,N-Dimethyltryptamine (DMT)
  • Section 18.5-Ecstasy (MDMA)
  • Section 18.6-Foxy
  • Section 18.7-LSD
  • Section 18.8-Mescaline (Peyote)
  • Section 18.9-Psilocybin
  • Section 18.10-Toonies (Nexus, 2C-B)
  • Chapter 19—Dissociative Drugs
  • Section 19.1-Dextromethorphan (DXM)
  • Section 19.2-PCP and Analogs
  • Section 19.3—Salvia Divinorum
  • Chapter 20—Inhalants
  • Chapter 21—Narcotics (Opioids)
  • Section 21.1—Introduction to Narcotics
  • Section 21.2—Buprenorphine
  • Section 21.3-Fentanyl
  • Section 21.4-Heroin
  • Section 21.5—Hydrocodone
  • Section 21.6—Hydromorphone
  • Section 21.7-Methadone
  • Section 21.8-Morphine
  • Section 21.9-Oxycodone
  • Section 21.10-Opium
  • Chapter 22—Sedatives (Depressants)
  • Section 22.1—Introduction to Depressants
  • Section 22.2-Barbiturates
  • Section 22.3—Benzodiazepines
  • Section 22.4-Kava
  • Chapter 23—Stimulants
  • Section 23.1—Introduction to Stimulants
  • Section 23.2—Amphetamine and Methylphenidate
  • Section 23.3-Benzylpiperazine (BZP)
  • Section 23.4-Cocaine
  • Section 23.5-Khat
  • Section 23.6-Kratom
  • Section 23.7—Methamphetamine
  • Section 23.8-Caffeine
  • Chapter 24—Tobacco, Nicotine, and E-Cigarettes
  • Chapter 25—New and Emerging Drugs of Abuse
  • Section 25.1—Introduction to Synthetic Drugs
  • Section 25.2-Bath Salts
  • Section 25.3-Spice/K2
  • Section 25.4—Flakka, Krokodil, N-Bomb, and Purple Drank
  • Part IV: The Causes and Consequences of Drug Abuse and Addiction
  • Chapter 26—Understanding Drug Abuse and Addiction
  • Section 26.1—Drug Addiction Is a Chronic Disease
  • Section 26.2—Common Risk and Protective Factors for Drug Use
  • Section 26.3-How Drugs Affect the Brain
  • Chapter 27—Prescription and Over-the-Counter Drug Abuse
  • Section 27.1—Prescription Drug Abuse
  • Section 27.2—Causes and Prevalence of Prescription Drug Abuse
  • Section 27.3—Cough and Cold Medicine (DXM and Codeine Syrup)
  • Chapter 28—Drug Interactions
  • Chapter 29—Legal, Financial, and Social Consequences of Drug Abuse
  • Section 29.1—Consequences of Drug Abuse
  • Section 29.2—Drugged Driving
  • Section 29.3—Drug Use and Crime
  • Section 29.4—Drug Use And Violence
  • Chapter 30—Health Consequences of Drug Addiction
  • Section 30.1—Poor Health Outcomes of Commonly Abused Drugs
  • Section 30.2—Substance Abuse and Medical Complications
  • Section 30.3—Early-Onset, Regular Cannabis Use Is Linked to IQ Decline
  • Chapter 31—Hepatitis and Substance Abuse
  • Chapter 32-HIV / AIDS and Drug Abuse
  • Chapter 33—Mental Illness and Addiction
  • Section 33.1—Addiction and Mental Health Disorders
  • Section 33.2—Study Parses Comorbidity of Cannabis Use and Social Anxiety
  • Section 33.3—Link between Marijuana Use and Psychiatric Disorders
  • Section 33.4—Prevention of Substance Abuse and Mental Illness
  • Chapter 34—Substance Abuse and Suicide Prevention
  • Part V: Drug Abuse Treatment and Recovery
  • Chapter 35—Recognizing Drug Use
  • Section 35.1—Signs of Drug Use
  • Section 35.2-Am I Drug Addicted?
  • Chapter 36—Responding to Drug Abuse Emergencies
  • Chapter 37—Drug Abuse Intervention
  • Chapter 38—Medical Professionals Need to Identify Substance Use Disorders
  • Chapter 39—Detoxification
  • Chapter 40—Treatment Approaches for Drug Addiction
  • Section 40.1—Treatment for Drug Addiction Overview
  • Section 40.2—Medication and Counseling Treatment
  • Section 40.3—Treatment for Methamphetamine Addiction
  • Section 40.4—Vaccines For Drug Abuse
  • Section 40.5—Addressing Co-Occurring Disorders in Different Settings
  • Chapter 41—Supporting Substance Abuse Recovery
  • Section 41.1—Mutual Support Groups
  • Section 41.2—Peer Recovery Support Services
  • Section 41.3—Recovery Services
  • Chapter 42—Know Your Rights When in Recovery from Substance Abuse
  • Chapter 43—Employee Assistance Programs (EAPs) for Substance Abuse
  • Chapter 44—Drug Abuse Treatment in the Criminal Justice System
  • Part VI: Drug Abuse Testing and Prevention
  • Chapter 45—Effective Public Health Responses to Drug Abuse
  • Chapter 46—Drug Abuse Prevention Begins at Home
  • Section 46.1-Talking to Your Child about Drugs
  • Section 46.2—Protecting Your Children from Prescription Drugs in Your Home
  • Section 46.3—Information for Parents about Club Drugs
  • Section 46.4—Family-Based Intervention for Teenage Drug Abuse
  • Chapter 47-Drug Testing
  • Section 47.1—Overview of Drug Testing
  • Section 47.2—Home Use Drug Testing
  • Chapter 48—Drug Abuse Testing and Prevention in Schools
  • Section 48.1—Drug Testing in Schools
  • Section 48.2—Drug Use Prevention Education in Schools
  • Chapter 49—Preventing Drug Abuse in the Workplace
  • Section 49.1—Drug-Free Workplace Policies
  • Section 49.2—Drug Testing in the Workplace
  • Chapter 50—Social Media and Substance Misuse Prevention
  • Chapter 51—Federal Drug Abuse Prevention Campaigns
  • Section 51.1—National Campaigns: An Overview
  • Section 51.2—Drug Abuse Prevention Programs
  • Section 51.3—New Funding Proposed to Address the Prescription Opioid Abuse and Heroin Use Epidemic
  • Section 51.4—PEERx Prescription Drug Abuse Prevention Campaign
  • Part VII: Additional Help and Information
  • Chapter 52—Glossary of Terms Related to Drug Abuse
  • Chapter 53—Glossary of Street Terms for Drugs of Abuse
  • Chapter 54—Directory of State Substance Abuse Agencies
  • Chapter 55—Directory of Organizations Providing Information about Drug Abuse